Travere Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
FILSPARI received FDA approval as the first therapy for FSGS without nephrotic syndrome, based on robust phase III data showing significant reductions in proteinuria and improved kidney outcomes. The launch leverages existing infrastructure, targets over 30,000 eligible US patients, and is expected to drive durable growth.
-
Significant progress was highlighted across rare disease programs, with FILSPARI showing strong commercial momentum in IgA nephropathy and an anticipated rapid launch in FSGS pending April FDA approval. The HCU program is restarting phase III, and the company remains financially strong with patent protection through 2033.
-
Record growth achieved in rare kidney disease therapies, with FILSPARI showing strong clinical and commercial momentum in IgA nephropathy and promising data in FSGS. Regulatory engagement for FSGS is ongoing, and the HARMONY phase III study for pegtibatinase in HCU is restarting this quarter.
Fiscal Year 2025
-
Record 2025 revenue and patient growth driven by FILSPARI's strong adoption in IgA nephropathy, with continued momentum expected in 2026. Pipeline advanced with FSGS sNDA and pegtibatinase Phase 3, while financials strengthened by milestone payments and robust sales.
-
Key priorities include FILSPARI's strong launch in IgA nephropathy, an sNDA for FSGS with a potential broad label, and the restart of pegtibatinase's phase 3 trial for HCU. Physician and payer feedback supports broad access, and clinical programs are well-capitalized.
-
Management highlighted strong progress in rare kidney disease therapies, with FILSPARI's FSGS approval on track for January and robust commercial performance in IgA nephropathy. Financial position is solid, supporting continued pipeline execution and future growth.
-
Late-breaking data reinforced sparsentan's benefit in FSGS, with strong reduction in proteinuria and kidney failure risk. Regulatory review is on track for January, with a broad label requested and rapid launch expected. Financial position remains strong, supporting ongoing pipeline investments.
-
Strong progress in rare kidney disease therapies, with an anticipated FSGS FDA decision in January and robust IgAN uptake. Financial position is solid, supporting ongoing R&D and commercial expansion, while pegtibatinase advances toward phase three restart.
-
Q3 saw robust revenue growth driven by FILSPARI's strong performance in IgA nephropathy, with net sales up over 155% year-over-year. The company is preparing for a potential FSGS launch, has strengthened its financial position, and continues to advance its pipeline.
-
Key priorities include expanding FILSPARI in IgA nephropathy and seeking FDA approval for FSGS, supported by strong clinical data and regulatory engagement. FSGS is viewed as a larger commercial opportunity, with recent REMS changes and competitive dynamics favoring growth.
-
Filspari achieved strong growth and expanded access in IgA nephropathy, aided by REMS modifications and payer support. The company anticipates FSGS approval in January and is advancing its pegtibatinase program for HCU, with a focus on broadening access and combination therapies.
-
FDA approved a key REMS modification for sparsentan, expected to expand access and align monitoring with standard care. Commercial momentum is strong, with new guidelines and real-world data supporting broader adoption. The FSGS program is advancing with a focus on proteinuria as a regulatory endpoint.
-
FILSPARI continues to gain traction as foundational care in IgA nephropathy, with strong commercial uptake, broad payer access, and evolving KDIGO guidelines supporting its use. Regulatory milestones include a REMS modification and a pivotal FSGS indication, while pegtibatinase advances toward phase III for HCU.
-
Q2 2025 saw record FILSPARI sales and strong year-over-year revenue growth, driven by expanding adoption in IgA nephropathy and progress toward FSGS approval. Robust financials, new clinical data, and anticipated regulatory milestones position the company for continued growth.
-
The conference highlighted strong momentum for FILSPARI in rare kidney diseases, with regulatory progress in FSGS and IgA nephropathy, expanding commercial uptake, and a robust financial position. Upcoming milestones include regulatory decisions, ex-U.S. launches, and pipeline expansion.
-
FILSPARI’s full approval and label expansion have driven strong growth in IgA nephropathy, with further momentum expected from upcoming KDIGO guidelines and potential REMS modification. Regulatory progress in FSGS and ongoing pipeline expansion position the company for sustained growth.
-
FILSPARI net sales surged 182% year-over-year, with strong uptake in IgAN and preparations for FSGS launch underway. Q1 revenue grew 90% to $75.9M, and the company remains well-capitalized with $322.2M in cash, expecting further growth and milestone payments.
-
FILSPARI achieved full approval for IgA nephropathy, supported by new guidelines and strong payer access, and is poised for expansion into FSGS with consistent efficacy. Pegtibatinase development in HCU continues, addressing significant unmet needs, with manufacturing issues being resolved.
-
The conference highlighted strategic priorities in rare kidney and metabolic diseases, with FILSPARI driving growth in IgA nephropathy and a regulatory path emerging for FSGS. Pegtibatinase advances in HCU, and combination therapy is set to shape future treatment paradigms.
-
FILSPARI is advancing toward FDA submission for FSGS, leveraging robust DUPLEX and DUET trial data and PARASOL analyses supporting proteinuria as a key endpoint. If granted priority review, approval could occur by year-end, potentially making FILSPARI the first approved FSGS therapy.
-
Significant innovation is reshaping rare kidney disease treatment, with Filspari achieving strong sales and broad access following full FDA approval for IgA nephropathy. Regulatory milestones, international expansion, and a robust pipeline in FSGS and HCU position the company for continued growth.
Fiscal Year 2024
-
Full FDA approval of FILSPARI in IgA nephropathy drove a 40% sequential sales increase in Q4 2024, with net product sales reaching $73.5 million for the quarter and $226.7 million for the year. The company is well-capitalized and expects continued strong growth in 2025.
-
Full approval and updated guidelines have driven strong demand for the lead therapy in IgA nephropathy, with expanded access and increased physician adoption. Regulatory consensus on proteinuria as an endpoint paves the way for FSGS approval, while financial flexibility supports ongoing growth.
-
Significant progress in rare kidney disease therapies, with Filspari's strong IgAN launch, broadening payer access, and anticipated REMS modification. FSGS regulatory discussions and new therapy launches are expected to drive further growth in 2025.
-
FILSPARI is fully approved for IgA nephropathy and shows strong, sustained efficacy, with plans to expand into FSGS based on new regulatory consensus around proteinuria as a surrogate endpoint. The company anticipates potential FSGS approval by end of next year and is also advancing pegtibatinase for HCU.
-
Full approval of FILSPARI in IgAN has driven strong commercial uptake, while FSGS development is advancing with regulatory alignment on proteinuria endpoints and a Type C FDA meeting scheduled. Pegtibatinase phase III is paused for manufacturing improvements, with plans to resume in 2026.
-
Full FDA approval and expanded label for FILSPARI drove over 30% sequential sales growth and broadened patient reach, with strong financial performance and high compliance rates. Regulatory progress continues for FSGS, and cash runway extends into 2028.
-
Enrollment in the phase III HARMONY study for pegtibatinase in HCU is paused to address manufacturing scale-up challenges, with re-enrollment expected in 2026. Current patients remain on treatment, and financial guidance reflects a shift in R&D expenses.
-
Filspari received full FDA approval with an expanded label and strong two-year data, doubling its addressable market. Updated guidelines and positive physician feedback support earlier, broader use, with commercial acceleration expected in Q4 and into next year.
-
Filspari received full FDA approval for IgA nephropathy, expanding its label and eligible patient population. Clinical data show superior proteinuria reduction and kidney function preservation versus irbesartan, with a strong safety profile and no new safety signals.
-
FILSPARI continues to gain traction as a foundational therapy for IgA nephropathy, with full FDA approval and expanded guidelines expected to further grow its market. The company is advancing pegtibatinase for HCU and pursuing additional indications for FILSPARI, including FSGS.
-
FILSPARI delivered record Q2 sales and demand, with strong prescriber growth and operational efficiencies. Anticipated full approval and updated KDIGO guidelines are expected to expand the addressable patient population and accelerate uptake, supporting long-term growth.
-
Focused on rare kidney and metabolic diseases, the company is driving growth with FILSPARI, expecting full approval and label expansion by September. Strong clinical data, high patient satisfaction, and robust financials support continued pipeline advancement and global partnerships.
-
The conference highlighted strong commercial momentum for Filspari in IgA nephropathy, robust payer coverage, and high patient compliance. Key milestones include a September PDUFA date for full approval, ongoing FSGS endpoint discussions, and phase III HCU data expected in 2026.